May 15, 2020 / 1:10 PM / 21 days ago

BRIEF-Legochem Biosciences And Iksuda Enter Licensing Agreement For Antibody Drug Conjugate Program

May 15 (Reuters) - LegoChem Biosciences Inc:

* LEGOCHEM BIOSCIENCES AND IKSUDA ENTER LICENSING AGREEMENT FOR ANTIBODY DRUG CONJUGATE PROGRAM

* LEGOCHEM BIOSCIENCES INC - WORLDWIDE LICENSE AGREEMENT WITH IKSUDA THERAPEUTICS FOR DEVELOPMENT AND COMMERCIALIZATION OF LCB73

* LEGOCHEM BIOSCIENCES INC - UNDER TERMS OF AGREEMENT, IKSUDA WILL MAKE AN UPFRONT PAYMENT OF $5 MILLION

* LEGOCHEM BIOSCIENCES INC - CO IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS OF UP TO $222 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below